menu
    • menu

    Company profile for Oncimmune

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oncimmune is a pioneer, a leader and an expert in early cancer detection and improved cancer outcomes. Our range of diagnostic tests assist clinicians to identify the presence of cancer on average four years before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments. Oncimmune’s patented platform technology, EarlyCDT®, has been dev...
    Oncimmune is a pioneer, a leader and an expert in early cancer detection and improved cancer outcomes. Our range of diagnostic tests assist clinicians to identify the presence of cancer on average four years before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments. Oncimmune’s patented platform technology, EarlyCDT®, has been developed to detect multiple solid tumour types. EarlyCDT® Lung measures blood levels of a panel of seven autoantibodies to tumour-associated antigens that are linked to lung cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Oncimmuneunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Clinical Sciences Building Hucknall Road Nottingham NG5 1PB
    Telephone
    Telephone
    +44 115 8231869
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oncimmune.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncimmune
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/OncimmuneECDT?ref

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oncimmune/Medicines Discovery Catapult win UK government funding
    Oncimmune/Medicines Discovery Catapult win UK government funding

    05 Oct 2020

    // Lucy Parsons PHARMATIMES

    http://www.pharmatimes.com/news/oncimmunemedicines_discovery_catapult_win_uk_government_funding_for_covid-19_research_tool_1352571

    Lucy Parsons PHARMATIMES
    05 Oct 2020
    Share Share
    Oncimmune partners with Genentech to profile samples from rheumatology trials
    Oncimmune partners with Genentech to profile samples from rheumatology trials

    23 Sep 2020

    // Lucy Parsons PHARMATIMES

    http://www.pharmatimes.com/news/oncimmune_partners_with_genentech_to_profile_samples_from_rheumatology_trials_1351153

    Lucy Parsons PHARMATIMES
    23 Sep 2020
    Share Share
    Oncimmune signs major immune profiling contract with Swiss pharma giant Roche
    Oncimmune signs major immune profiling contract with Swiss pharma giant Roche

    28 May 2020

    // PROACT IVEINVESTORS

    https://www.proactiveinvestors.co.uk/companies/news/920583/oncimmune-signs-major-immune-profiling-contract-with-swiss-pharma-roche-920583.html

    PROACT IVEINVESTORS
    28 May 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search